References:
  1. Zucca E, Copie-Bergman C, Ricardi U, et al. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 Suppl 6:vi144.
  2. Hu, Q., Zhang, Y., Zhang, X. et al. Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori infection: a review of current diagnosis and management. Biomark Res 4, 15 (2016). https://doi.org/10.1186/s40364-016-0068-1
  3. Sebagh M, Flejou JF, Potet F. Lymphoma of the gastric stump. J Clin Gastroenterol 1995;20:147–50.
  4. Oshita H, Tanemura H, Kanno A et al. Malignant lymphoma occurring in the residual stomach following gastrectomy: plus discussion based on the literature in Japan. Gastric Cancer 2003; 6: 60-3.
  5. Jawad, A., Bar, A.H., Merianos, D. et al. MALT Lymphoma of the Gastric Remnant After Roux-en-Y Gastric Bypass. J Gastrointest Canc 43, 194–197 (2012). https://doi.org/10.1007/s12029-012-9386-1
  6. De Roover A, Detry O, de Leval L. Report of two cases of gastric cancer after bariatric surgery: lymphoma of the bypassed stomach and gastrointestinal stromal tumor (GIST) after vertical banded gastroplasty. Obes Surg. 2006;16:928–31.
  7. Felipe Suarez, Olivier Lortholary, Olivier Hermine, Marc Lecuit; Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 2006; 107 (8): 3034–3044. doi: https://doi.org/10.1182/blood-2005-09-3679
  8. Cavalli F, Isaacson PG, Gascoyne RD, Zucca E. MALT Lymphomas. Hematology (Am Soc Hematol Educ Program). 2001: 241-258.
  9. Morse HC III, Kearney JF, Isaacson PG, Carroll M, Fredrickson TN, Jaffe ES. Cells of the marginal zone: origins, function and neoplasia. Leuk Res. 2001;25: 169-178.
  10. Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer. 2004;4: 644-653
  11. Du M, Isaacson P. Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol. 2002;3: 97-104.
  12. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342:575.
  13. Kuo S., Yeh, K., Wu, M. et al. First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma. Sci Rep 7, 14333 (2017). https://doi.org/10.1038/s41598-017-14102-8.
  14. Sung-Hsin , Kuo. “First-Line Antibiotic Therapy in Helicobacter Pylori-Negative Low-Grade Gastric Mucosa-Associated Lymphoid Tissue Lymphoma.” Nature, 30 Oct. 2017, www.nature.com/articles/s41598-017-14102-8.
  15. Farinha P, Gascoyne RD. Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol. 2005;23: 6370-6378.
  16. Liu, H. et al . T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication.Gastroenterology. 122 , 1286–1294 (2002).
  17. Liu, H. et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet. 357, 39–40 (2001).
  18. Nakamura, T., Nakamura, S., Yonezumi, M., Seto, M. & Yokoi, T. The t(11;18)(q21; q21) translocation in H. pylori-negative low-grade gastric MALT lymphoma. AmJ Gastroenterol. 95, 3314–3315 (2000).
  19. Ruskoné-Fourmestraux A, Fischbach W, Aleman BMP, et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011;60:747-758.
  20. Hongtao Ye, Hongxiang Liu, Markus Raderer, Andreas Chott, Agnes Ruskone-Fourmestraux, Andrew Wotherspoon, Martin J. S. Dyer, Shih-Sung Chuang, Ahmet Dogan, Peter G. Isaacson, Ming-Qing Du; High incidence of t(11;18)(q21;q21) in Helicobacter pylori–negative gastric MALT lymphoma. Blood 2003; 101 (7): 2547–2550. doi: https://doi.org/10.1182/blood-2002-10-3167
  21. Levy M, Copie-Bergman C, Gameiro C, et al. Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol 2005;23:5061–6.
  22. Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin’s lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005;23:1979–83.
  23. Hitchcock S, Ng AK, Fisher DC, et al. Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 2002; 52:1058.
  24. Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003; 21:4157.
  25. Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin’s lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005; 23:1979.
  26. Gold, Douglas, Miller, Robert, Peterson, Ivy, et al. Radiotherapy for Malignancy in Patients with Scleroderma: The Mayo Experience. International Journal of Radiation Oncology. 2007: Vol 67, Issue 2, Pg:559-567
  27. Koch P, del Valle F, Berdel WE, et al. Primary gastrointestinal non-Hodgkin’s lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma—results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol 2001;19:3874–83
  28. Vrieling C, de Jong D, Boot H, et al. Long-term results of stomach-conserving therapy in gastric MALT lymphoma. Radiother Oncol 2008;87:405–11